This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Houssiau, F. Articles by Renauld, J-C. Search for Related Content PubMed PubMed Citation Articles by Houssiau, F. Articles by Renauld, J-C. Social Bookmarking                         What's this?

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

Department of Rheumatology, UCL 5390

C. Lefebvre

Department of General Internal Medicine, St-Luc University Hospital, Avenue Hippocrate 10, B-1200 Bruxelles

M. Vanden Berghe

Department of Rheumatology, UCL 5390

M. Lambert

Department of General Internal Medicine, St-Luc University Hospital, Avenue Hippocrate 10, B-1200 Bruxelles

J-P. Devogelaer

Department of Rheumatology, UCL 5390

J-C. Renauld

Experimental Medicine Unit, Institute of Cellular and Molecular Pathology, Ludwig Institute for Cancer Research, Catholic University of Louvain in Brussels, Belgium

We investigated whether serum titers of interleukin 10 (IL-10), a cytokine known to shift lymphocyte responses towards humoral immunity, reflect disease activity in systemic lupus erythematosus (SLE). Sera from 72 SLE patients, 25 RA patients and 30 healthy controls were tested for IL-10 by ELISA. Low titers of IL-10 were detected in the serum of 37.5% of SLE patients and in 24% of RA patients but in only 3% of healthy controls. Interestingly, serum IL-10 titers in SLE patients were positively correlated with the SLE Disease Activity Index (SLEDAI) and with anti-DNA antibody titers, but negatively with complement fraction C3 levels. These results indicate that serum IL-10 values reflect SLE disease activity and suggest that overexpression of IL-10 might play a pathogenic role in severe lupus disease.

Key Words: interleukin-10 • disease activity

Lupus, Vol. 4, No. 5, 393-395 (1995)
DOI: 10.1177/096120339500400510


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G H Stummvoll, R D Fritsch, B Meyer, E Hoefler, M Aringer, J S Smolen, and G Steiner Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus Ann Rheum Dis, January 1, 2009; 68(1): 110 - 116. [Abstract] [Full Text] [PDF]

				A. Rahman and D. A. Isenberg Systemic Lupus Erythematosus N. Engl. J. Med., February 28, 2008; 358(9): 929 - 939. [Full Text] [PDF]

				K. Tenbrock, Y.-T. Juang, V. C. Kyttaris, and G. C. Tsokos Altered signal transduction in SLE T cells Rheumatology, October 1, 2007; 46(10): 1525 - 1530. [Abstract] [Full Text] [PDF]

				P. Bobe, D. Bonardelle, K. Benihoud, P. Opolon, and M. K. Chelbi-Alix Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice Blood, December 15, 2006; 108(13): 3967 - 3975. [Abstract] [Full Text] [PDF]

				J-S F Sanders, M G Huitma, C G M Kallenberg, and C A Stegeman Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse Ann Rheum Dis, November 1, 2006; 65(11): 1484 - 1489. [Abstract] [Full Text] [PDF]

				J. Astermark, J. Oldenburg, A. Pavlova, E. Berntorp, A.-K. Lefvert, and for the MIBS Study Group Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A Blood, April 15, 2006; 107(8): 3167 - 3172. [Abstract] [Full Text] [PDF]

				L C W Lit, C K Wong, L S Tam, E K M Li, and C W K Lam Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus Ann Rheum Dis, February 1, 2006; 65(2): 209 - 215. [Abstract] [Full Text] [PDF]

				B R Lauwerys and E K Wakeland Genetics of lupus nephritis Lupus, January 1, 2005; 14(1): 2 - 12. [Abstract] [PDF]

				D M Chang, S J Chu, H C Chen, S Y Kuo, and J H Lai Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus Ann Rheum Dis, December 1, 2004; 63(12): 1623 - 1626. [Abstract] [Full Text] [PDF]

				H. Schotte, M. Gaubitz, P. Willeke, N. Tidow, G. Assmann, W. Domschke, and B. Schluter Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response Rheumatology, November 1, 2004; 43(11): 1357 - 1363. [Abstract] [Full Text] [PDF]

				F. A. Houssiau Management of Lupus Nephritis: An Update J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704. [Full Text] [PDF]

				J. W. Steinke, E. Barekzi, J. Hagman, and L. Borish Functional Analysis of -571 IL-10 Promoter Polymorphism Reveals a Repressor Element Controlled by Sp1 J. Immunol., September 1, 2004; 173(5): 3215 - 3222. [Abstract] [Full Text] [PDF]

				V. C. Kyttaris, Y.-T. Juang, K. Tenbrock, A. Weinstein, and G. C. Tsokos Cyclic Adenosine 5'-Monophosphate Response Element Modulator Is Responsible for the Decreased Expression of c-fos and Activator Protein-1 Binding in T Cells from Patients with Systemic Lupus Erythematosus J. Immunol., September 1, 2004; 173(5): 3557 - 3563. [Abstract] [Full Text] [PDF]

				C Gorman, M Leandro, and D Isenberg Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Lupus, May 1, 2004; 13(5): 312 - 316. [Abstract] [PDF]

				C C Mok and C S Lau Pathogenesis of systemic lupus erythematosus J. Clin. Pathol., July 1, 2003; 56(7): 481 - 490. [Abstract] [Full Text] [PDF]

				J Ronnelid, A Tejde, L Mathsson, K Nilsson-Ekdahl, and B Nilsson Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an Fc{gamma}RII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE Ann Rheum Dis, January 1, 2003; 62(1): 37 - 42. [Abstract] [Full Text] [PDF]

				G. Heine, U. Sester, M. Sester, J. E. Scherberich, M. Girndt, and H. Kohler A shift in the Th1/Th2 ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1790 - 1794. [Abstract] [Full Text] [PDF]

				Y. Miura, C. J. Thoburn, E. C. Bright, W. Chen, S. Nakao, and A. D. Hess Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD Blood, September 18, 2002; 100(7): 2650 - 2658. [Abstract] [Full Text] [PDF]

				Z. Yin, G. Bahtiyar, N. Zhang, L. Liu, P. Zhu, M. E. Robert, J. McNiff, M. P. Madaio, and J. Craft IL-10 Regulates Murine Lupus J. Immunol., August 15, 2002; 169(4): 2148 - 2155. [Abstract] [Full Text] [PDF]

				M Ehrenfeld, M Blank, Y Shoenfeld, and M Hidvegi AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease Lupus, September 1, 2001; 10(9): 622 - 627. [Abstract] [PDF]

				A. W. Gibson, J. C. Edberg, J. Wu, R. G. J. Westendorp, T. W. J. Huizinga, and R. P. Kimberly Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus J. Immunol., March 15, 2001; 166(6): 3915 - 3922. [Abstract] [Full Text] [PDF]

				C K Wong, C. Y Ho, E. Li, and C. Lam Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus Lupus, October 1, 2000; 9(8): 589 - 593. [Abstract] [PDF]

				I. Gunnarsson, B. Nordmark, A. Hassan Bakri, G. Grondal, P. Larsson, J. Forslid, L. Klareskog, and B. Ringertz Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment--the role of IL-10 and HLA Rheumatology, August 1, 2000; 39(8): 886 - 893. [Abstract] [Full Text] [PDF]

				G. S Dean, J. Tyrrell-Price, E. Crawley, and D. A Isenberg Cytokines and systemic lupus erythematosus Ann Rheum Dis, April 1, 2000; 59(4): 243 - 251. [Full Text]

				K Ohtsuka, J D Gray, M M Stimmler, and D A Horwitz The relationship between defects in lymphocyte production of transforming growth factor-{beta}1 in systemic lupus erythematosus and disease activity or severity Lupus, February 1, 1999; 8(2): 90 - 94. [Abstract] [PDF]

				G G Illei and J H Klippel Novel approaches in the treatment of lupus nephritis Lupus, November 1, 1998; 7(9): 644 - 648. [Abstract] [PDF]

				M. CUTOLO, A. SULLI, B. VILLAGGIO, B. SERIOLO, and S. ACCARDO Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus Ann Rheum Dis, October 1, 1998; 57(10): 573 - 577. [Full Text]

				B R Lauwerys and F A Houssiau Cytokines: clues to the pathogenesis of SLE Lupus, May 1, 1998; 7(4): 211 - 213. [PDF]